Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Jun 11, 2021 12:54pm
223 Views
Post# 33372863

RE:Is this the year?

RE:Is this the year?My guess is we'll have definitive 360 day results for the first 25 patients by August 2022 and can apply for BTD and accelerated approval then. Since we have fast track status we should get the FDA response in 6 months - by January or February 2023. If nothing else works, FDA approval to commercialize should move the needle.

"Assuming that this phase II is positive, and eradicates this disease in a significant proportion of patients, then there is a pretty clear route to arriving at regulatory approval. We recently had a guidance from the FDA which very clearly states the type of patient we need to treat, and the endpoints, which are, that their cancer is effectively eradicated and that is sustained for a period of a year."

Dr. Michael Jewett, July 2018


valueman1 wrote: Many of us, myself included, are long time shareholders. Honestly can't say how long I've been invested in a position but at least 19 years. Many many false starts. Could this be a year of conclusive proof and numerous news releases to show us all what we believe to be a real cure for bladder ( et al) cancer. Anxious to see what unfolds 


<< Previous
Bullboard Posts
Next >>